Effect of antihypertensive drugs on insulin, glucose, and lipid metabolism.
about
Benefits and side effects of blood pressure lowering treatment: what was wrong with doxazosin in the ALLHAT?Erectile dysfunction in heart failure patients: a critical reappraisalRacial Disparity in the Associations of Cotinine with Insulin Secretion: Data from the National Health and Nutrition Examination Survey, 2007-2012Beta-blockers in the treatment of hypertension: new data, new directions.Impact of abdominal obesity on incidence of adverse metabolic effects associated with antihypertensive medications.Insulin resistance and hypertension.Treating hypertension while protecting the vulnerable islet in the cardiometabolic syndromePathophysiologic therapeutic targets in hypertension: a cardiological point of view.Prescribing patterns and therapeutic implications for diabetic hypertension in Bahrain.Antihypertensive drug treatment in a Swedish community: Skaraborg Hypertension and Diabetes Project.Doxazosin versus bendrofluazide: a comparison of the metabolic effects in British South Asians with hypertension.Cardiovascular disease prevention practices by U.S. Physicians for patients with diabetes.The secondary prevention of myocardial infarction by drug treatment; excluding lipid lowering agents.Antihypertensive therapy. Current issues and challenges.Losartan modulates muscular capillary density and reverses thiazide diuretic-exacerbated insulin resistance in fructose-fed rats.Blood pressure responses and metabolic effects of hydrochlorothiazide and atenolol.Metformin and blood pressure.Current therapeutic options in the management of diffuse idiopathic skeletal hyperostosis.Inhibition of the renin-angiotensin system and cardio-renal protection: focus on losartan and angiotensin receptor blockade.Drug therapy of the metabolic syndrome: minimizing the emerging crisis in polypharmacy.Diabetes mellitus and raised serum triglyceride concentration in treated hypertension--are they of prognostic importance? Observational study.Carvedilol versus cardioselective beta-blockers for the treatment of hypertension in patients with type 2 diabetes mellitus.Treating the metabolic syndrome.Concomitant calcium entry blockade and inhibition of the renin-angiotensin system: a rational and effective means for treating hypertension.Angiotensin receptor blocker and dihydropyridine calcium channel blocker combinations: an emerging strategy in hypertension therapy.Vascular endothelial ageing, heartbeat after heartbeat.Individualization of antihypertensive drug treatment.PROX1 gene variant is associated with fasting glucose change after antihypertensive treatment.Diuretics in clinical practice. Part II: electrolyte and acid-base disorders complicating diuretic therapy.The role of Beta-blockers as first-line therapy in hypertension.Lipid effects of antihypertensive medications.Epinephrine and the metabolic syndrome.The effect of antihypertensive drugs on chronic kidney disease: a comprehensive review.Paediatrics, insulin resistance and the kidney.Elevated fasting plasma insulin in a general aged population: an innocent companion of cardiovascular diseases.The place of alpha blockers in the treatment of hypertension.The place of diuretics in the treatment of hypertension in 1993: can we do better?Current issues in treating the hypertensive patient with diabetes: focus on diabetic nephropathy.Cardiovascular risk factors and the prediabetic syndrome.Insulin treatment, NIDDM and atherosclerosis
P2860
Q24799267-6ED48775-F8F1-4A21-A646-7994ABC4A112Q26853624-E808309A-8A43-4A00-90A2-21A355628329Q28354083-E8947EB7-FCC8-48CB-BA63-3109BE2F5A70Q31149036-CCDCC9B8-66C7-4C2E-87D4-9D9B882F03C1Q33609093-F06088BB-B3B8-4253-BDAB-3EA31761EEE0Q33697707-FCFA0F96-8C6F-407A-B380-CC7D55881713Q33840829-F31285A0-EE95-4C62-8673-7C611E070D58Q34142036-852A4411-2770-4E66-93C4-9521E597ED1AQ34449421-EE9B7C24-E4D7-4541-B198-E05872EB3151Q34629809-48EB9725-B348-4077-8E36-08B5485BBCB6Q34652730-00FD9DA0-5D87-450A-8807-34472C4C02F1Q34745500-D60CC359-390D-494E-BCE4-8FE3A77E3C85Q35251074-0D433789-2377-41C4-906B-80420E3C55C5Q35254610-A01D36EC-F918-4EE1-9026-10FF1EB0956EQ35669326-B91C9F6D-5F9D-4272-8664-96B1C9CF8E29Q35784679-78231283-B5AE-4B6E-A5C4-DFEC0A533589Q36098057-F610A06A-2B8B-4110-A7B5-2F0674BEFCD9Q36192754-C795019B-40BA-490D-9539-4BB7B71222FDQ36249947-58EE4CB6-D56F-431C-A6D5-23040FC4FACCQ36438737-EE420475-55FB-457E-9B67-74B45E8B25ADQ36600125-A469CEC1-524C-4D66-A9BB-489572D093D2Q36603238-F9AA6F73-17B7-4B98-B2FD-B7FA917D98C7Q36815978-374762F6-C0FA-4ACD-A5A8-931433A31F8DQ37135582-B1FE2537-0089-4ABA-B2E0-B0EC3AABA5B4Q37427232-FD2765B5-A142-4621-B45C-92D3C4F9A704Q37545073-F34E03AA-5883-4D1B-A0D0-2E5EF1EE14FBQ37577140-AE9A9DD5-587C-4A26-847F-837D8AD12ABCQ37622386-065B92DF-3A1D-4C15-AF30-D5CDDD61512EQ37679929-6C580F39-E8F4-4C18-B297-7A2CECCCA778Q37826118-2BD910B9-4492-4908-831A-BBADD1577715Q37950846-B8EB9E0A-99C8-4E4A-B1EE-ADFA74C35851Q37962417-491E810B-AF0F-4A09-AA17-97454D543B46Q38050872-ED45BAAD-7C8E-40B4-97BB-0F27BE937AF8Q38233797-14AAA1B8-290A-4493-89E2-6CBC83C9D355Q39442978-2C2046C1-075F-4640-9D84-234250A7C141Q40619283-A85CAD0C-1109-4AE9-AD46-C12DD38A6AC3Q40794702-C7B5B24B-212F-4FEC-BF4B-B1DB4D418024Q41127224-6A17B106-FDCB-4C72-905A-D7335D22DB0BQ41156161-3473C5C2-4A39-441C-89C4-27F42B54C55CQ41522282-E9BBFB47-6BF9-4D46-A0C5-392D6D0A174F
P2860
Effect of antihypertensive drugs on insulin, glucose, and lipid metabolism.
description
1991 nî lūn-bûn
@nan
1991年の論文
@ja
1991年学术文章
@wuu
1991年学术文章
@zh
1991年学术文章
@zh-cn
1991年学术文章
@zh-hans
1991年学术文章
@zh-my
1991年学术文章
@zh-sg
1991年學術文章
@yue
1991年學術文章
@zh-hant
name
Effect of antihypertensive drugs on insulin, glucose, and lipid metabolism.
@en
Effect of antihypertensive drugs on insulin, glucose, and lipid metabolism.
@nl
type
label
Effect of antihypertensive drugs on insulin, glucose, and lipid metabolism.
@en
Effect of antihypertensive drugs on insulin, glucose, and lipid metabolism.
@nl
prefLabel
Effect of antihypertensive drugs on insulin, glucose, and lipid metabolism.
@en
Effect of antihypertensive drugs on insulin, glucose, and lipid metabolism.
@nl
P356
P1433
P1476
Effect of antihypertensive drugs on insulin, glucose, and lipid metabolism.
@en
P2093
Lithell HO
P304
P356
10.2337/DIACARE.14.3.203
P407
P577
1991-03-01T00:00:00Z